RxDoctor Payments Data

Benoit Pineau, MD

Gastroenterology · St. Augustine, FLNPI 1619173309

Payments from drug & device makers

$394,877in general payments, 2019–2025

Across 743 payments — averaging $531.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$222K
  • Madrigal Pharmaceuticals$84K
  • Chugai Pharmaceutical Co., Ltd.$29K
  • AstraZeneca$20K
  • Regeneron Healthcare Solutions, Inc.$20K
  • AbbVie$7K
  • plus $13K from 40 others

What the payments were for

  • Consulting fees$1,7164%
  • Speaking & faculty fees$23,06255%
  • Travel & lodging$2,9547%
  • Food & beverage$13,98334%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$394,877 in reported general payments places this provider in the 90th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$417,071
Medicare patients
794
Services billed
10,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$280,800
XeljanzTofacitinib Citrate12$71,490
LinzessLinaclotide53$41,324
Pantoprazole Sodium612$10,011
Omeprazole299$5,565
Colestipol Hcl87$5,503
Ursodiol14$4,402
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates66$3,839
Famotidine201$3,746
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag29$3,547
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C21$2,902
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,580
Dicyclomine Hcl53$1,431
Budesonide DrBudesonide15$1,299
Sucralfate30$1,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,164$280,80011 claims
PfizerXeljanz$308$71,49012 claims
AbbVieLinzess$7,236$41,32453 claims
Braintree Laboratories, Inc.Suflave, Sutab$60$6,12745 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$853$2,90221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in St. Augustine

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →